Macquarie Group’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-751,788
Closed -$133M 1213
2025
Q3
$133M Sell
751,788
-174,766
-19% -$26M 0.16% 147
2025
Q2
$105M Buy
926,554
+20,327
+2% +$2.17M 0.13% 215
2025
Q1
$95.3M Buy
906,227
+21,847
+2% +$2.47M 0.12% 245
2024
Q4
$94.8M Sell
884,380
-2,895
-0.3% -$327K 0.12% 248
2024
Q3
$88.8M Sell
887,275
-79,277
-8% -$7.98M 0.1% 285
2024
Q2
$81.4M Sell
966,552
-66,629
-6% -$5.3M 0.09% 279
2024
Q1
$75.5M Buy
1,033,181
+45,827
+5% +$3.38M 0.09% 302
2023
Q4
$70.5M Sell
987,354
-4,464
-0.5% -$263K 0.08% 340
2023
Q3
$59.4M Buy
991,818
+154,648
+18% +$10.2M 0.07% 351
2023
Q2
$60.4M Buy
837,170
+19,187
+2% +$1.44M 0.07% 367
2023
Q1
$60.2M Buy
817,983
+17,387
+2% +$1.24M 0.07% 351
2022
Q4
$53.5M Sell
800,596
-471,578
-37% -$30.7M 0.06% 421
2022
Q3
$68.3M Buy
1,272,174
+15,544
+1% +$914K 0.08% 328
2022
Q2
$69.9M Buy
1,256,630
+40,368
+3% +$2.29M 0.08% 348
2022
Q1
$85.4K Buy
1,216,262
+214,437
+21% +$15.6M 0.06% 345
2021
Q4
$96.5M Sell
1,001,825
-31,754
-3% -$2.93M 0.08% 314
2021
Q3
$89.8M Buy
1,033,579
+81,881
+9% +$6.33M 0.08% 334
2021
Q2
$77.9M Buy
951,698
+175,272
+23% +$14.6M 0.06% 382
2021
Q1
$73.8M Sell
776,426
-657,743
-46% -$62.2M 0.1% 245
2020
Q4
$89M Buy
1,434,169
+222,088
+18% +$12.7M 0.13% 172
2020
Q3
$72.1M Buy
1,212,081
+22,570
+2% +$1.54M 0.12% 179
2020
Q2
$83M Buy
1,189,511
+78,496
+7% +$4.98M 0.14% 148
2020
Q1
$50.4M Buy
1,111,015
+86,273
+8% +$4.89M 0.1% 208
2019
Q4
$66.7M Buy
1,024,742
+127,118
+14% +$8.49M 0.1% 225
2019
Q3
$55.7M Buy
897,624
+54,707
+6% +$3.43M 0.09% 228
2019
Q2
$60M Buy
842,917
+56,193
+7% +$4.14M 0.1% 209
2019
Q1
$61.7M Buy
786,724
+82,066
+12% +$6.22M 0.11% 192
2018
Q4
$59.7M Buy
704,658
+105,336
+18% +$11.2M 0.12% 170
2018
Q3
$103M Sell
599,322
-37,250
-6% -$5.62M 0.17% 104
2018
Q2
$82.3M Buy
636,572
+15,982
+3% +$1.78M 0.14% 134
2018
Q1
$63.9M Buy
620,590
+29,527
+5% +$2.92M 0.12% 163
2017
Q4
$50.5M Sell
591,063
-151,182
-20% -$13.1M 0.09% 214
2017
Q3
$63M Sell
742,245
-12,861
-2% -$1.02M 0.11% 162
2017
Q2
$57.2M Buy
755,106
+162,020
+27% +$11.3M 0.1% 162
2017
Q1
$39.2M Buy
593,086
+65,435
+12% +$4.3M 0.07% 248
2016
Q4
$33.4M Buy
527,651
+89,832
+21% +$5.67M 0.06% 278
2016
Q3
$27.9M Sell
437,819
-465,084
-52% -$34.1M 0.05% 322
2016
Q2
$67.2M Buy
902,903
+468,629
+108% +$34.8M 0.07% 240
2016
Q1
$29M Buy
434,274
+61,807
+17% +$3.76M 0.06% 272
2015
Q4
$25.2M Sell
372,467
-39,294
-10% -$2.43M 0.05% 292
2015
Q3
$22M Buy
411,761
+62,236
+18% +$3.78M 0.05% 321
2015
Q2
$22M Sell
349,525
-19,364
-5% -$1.06M 0.04% 346
2015
Q1
$17.7M Buy
368,889
+149,502
+68% +$5.73M 0.03% 405
2014
Q4
$7.28M Buy
219,387
+123,207
+128% +$4.01M 0.02% 607
2014
Q3
$2.82M Hold
96,180
0.01% 893
2014
Q2
$3.74M Hold
96,180
0.01% 803
2014
Q1
$4.04M Hold
96,180
0.01% 739
2013
Q4
$3.16M Sell
96,180
-81,272
-46% -$2.65M 0.01% 787
2013
Q3
$4.79M Sell
177,452
-22,923
-11% -$645K 0.01% 628
2013
Q2
$4.68M Buy
+200,375
New +$3.6M 0.01% 611

Other funds holding LGND

Macquarie Group's LGND Position: Q4 2025 in Review

Macquarie Group sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 751,788 shares — an estimated $133M sold.

Macquarie Group first reported a position in LGND in Q2 2013 and held it in 50 quarters. The position peaked at $133M in Q3 2025. 349 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Macquarie Group reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 751,788 Ligand Pharmaceuticals shares in Q4 2025, an estimated $133M.
  • Macquarie Group first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 50 quarters.
  • Macquarie Group's Ligand Pharmaceuticals position peaked at $133M in Q3 2025.
  • 349 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.